Reneo Pharmaceuticals logo

Reneo PharmaceuticalsNASDAQ: RPHM

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

08 April 2021

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$60.84 M
-80%vs. 3y high
37%vs. sector
-vs. 3y high
-vs. sector
-77%vs. 3y high
36%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Fri, 04 Oct 2024 13:30:00 GMT
$18.20(0.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

Included in screeners

No data

RPHM Latest News

Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure
globenewswire.com02 October 2024 Sentiment: POSITIVE

– Combined company to trade on Nasdaq under ticker “OKUR” – Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) (“Reneo”) today announced the results of the special meeting of its stockholders held on September 26, 2024.

Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results
globenewswire.com13 August 2024 Sentiment: POSITIVE

IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the second quarter ended June 30, 2024.

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
prnewswire.com24 June 2024 Sentiment: POSITIVE

NEW YORK , June 24, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), relating to its proposed merger with OnKure, Inc. Under the terms of the agreement, Reneo stockholders are expected to own approximately 31% of the combined company.

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
globenewswire.com21 June 2024 Sentiment: NEGATIVE

NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Reneo Pharmaceuticals, Inc. (Nasdaq:  RPHM ), relating to its proposed merger with OnKure, Inc. Under the terms of the agreement, Reneo stockholders are expected to own approximately 31% of the combined company.

Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study
Zacks Investment Research15 December 2023 Sentiment: NEGATIVE

Reneo (RPHM) loses 83% following the failure of the mid-stage pivotal study of its only pipeline candidate, mavodelpar, to treat primary mitochondrial myopathies in adults. It cuts the workforce by 70%.

Reneo Pharmaceuticals: Buy Before Upcoming Pivotal Data Drop
Seeking Alpha29 October 2023 Sentiment: POSITIVE

Reneo Pharmaceuticals is developing mitochondrial disease therapies, with its lead program being mavodelpar or REN001. Mavodelpar has shown promising results in increasing fatty acid oxidation and improving muscle strength in clinical trials. The company expects topline results from a pivotal trial in primary mitochondrial myopathy in 4Q23, with potential approval and launch in late 2024.

What type of business is Reneo Pharmaceuticals?

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

What sector is Reneo Pharmaceuticals in?

Reneo Pharmaceuticals is in the Healthcare sector

What industry is Reneo Pharmaceuticals in?

Reneo Pharmaceuticals is in the Biotechnology industry

What country is Reneo Pharmaceuticals from?

Reneo Pharmaceuticals is headquartered in United States

When did Reneo Pharmaceuticals go public?

Reneo Pharmaceuticals initial public offering (IPO) was on 08 April 2021

What is Reneo Pharmaceuticals website?

https://reneopharma.com

Is Reneo Pharmaceuticals in the S&P 500?

No, Reneo Pharmaceuticals is not included in the S&P 500 index

Is Reneo Pharmaceuticals in the NASDAQ 100?

No, Reneo Pharmaceuticals is not included in the NASDAQ 100 index

Is Reneo Pharmaceuticals in the Dow Jones?

No, Reneo Pharmaceuticals is not included in the Dow Jones index

When was Reneo Pharmaceuticals the previous earnings report?

No data

When does Reneo Pharmaceuticals earnings report?

The next expected earnings date for Reneo Pharmaceuticals is 13 November 2024